A PHASE 2 OPEN-LABEL STUDY TO ASSESS THE SAFETY AND IMMUNOGENICITY OF AN ALUM-ADJUVANTED CHIKUNGUNYA VIRUS-LIKE PARTICLE (VLP) VACCINE IN PRIOR RECIPIENTS OF OTHER ALPHAVIRUS VACCINES VERSUS ALPHAVIRUS NAÏVE CONTROLS

Authors
Category Primary study
JournalAmerican Journal of Tropical Medicine and Hygiene
Year 2023
This article has no abstract
Epistemonikos ID: ca22dea43426d4bcac279420f3e3886d508f63af
First added on: Apr 30, 2026